pcc Practice Builder™ Emerges as a Growth Engine for Medical Practices in 2026 
BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the...
Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and...
Evox Therapeutics Presents Progress Across its DeliverEX® Platform Highlighting Advances in Exosome-Mediated Delivery of Genetic Medicines Including Gene Editing and RNA Therapeutics
Six Upcoming Presentations at the Annual Meetings of the American Society of Gene and Cell Therapy (ASGCT) and of the...
Reflect Scientific Inc Reports First Quarter 2023 Results
OREM, Utah, May 12, 2023 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (OTCQB: RSCF), a provider of diverse products and services...
IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
Presented positive INB-100 data showing long-term complete remissions (CR) and elevated gamma-delta T cell levels in 100% of evaluable treated...
Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market
MONTREAL, May 12, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines...
Spectral Medical Announces First Quarter Results and Provides Corporate Update
New Trial Sites Enroll 60% of New Patient Enrollments Since the Beginning of April Tigris Patient Enrollment at 58 Patients...
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results
-- New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce potential...
SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)
SCYNEXIS is receiving an upfront payment of $90 million with future performance-based milestone payments of up to $503 million and...
Vyant Bio Announces Last Day of Trading on Nasdaq and Filing of Form 15 for Voluntary Nasdaq Delisting and SEC Deregistration
CHERRY HILL, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a...
Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that...
Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update
Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson’s diseaseCompany is on track to submit application for...
Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash...
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update Capital Markets Day held in April highlighted...
Psychedelic Science 2023 Announces Sessions and Select Featured Speakers for the Therapy and Practitioners Tracks for June Conference
Dr. Rachel Yehuda to Lead Discussions on Therapeutic Application of Psychedelics Additional Featured Speakers Include Dr. Julie Holland, Dr. Carl...
LifeMD, Inc. Reports First Quarter 2023 Results; Record Revenues and Adjusted EBITDA
Record first quarter 2023 consolidated revenue of $33.1 million, up 14% from the same year-ago period.Record Adjusted EPS of $0.06...
Humacyte First Quarter 2023 Financial Results and Business Update
- Human Acellular Vessel™ (HAV™) granted second RMAT designation by the FDA, for Vascular Trauma - - Completion of enrollment...
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
– Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline – Advancing registration program...
Bio-Path Holdings Reports First Quarter 2023 Financial Results
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH),...
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update
Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during...